ClinicalTrials.gg
CompletedNCT06041217STEP12Updated May 18, 2026Results posted

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

A Phase 3 interventional study of Semaglutide and Placebo in Overweight and Obesity, sponsored by Novo Nordisk A/S. Completed at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
33rd of 143
242 · median 100
Started
2023
with 14 others
Phase 3
42 of 143
10 open now
Registered
67th of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 33rd largest by enrollment, is one of 15 that started in 2023, is one of 42 in phase 3, and was the 67th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls with the study doctor or staff.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 242 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 18 years at the time of signing .
  • (BMI) of greater than or equal to 24 and less than 28 kilogram per square meter ( kg/m\^2) with the presence of at least one weight related complication (treated or untreated): Type 2 diabetes (T2D), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease or BMI greater than or equal to 28 and less 30 kg/m\^2, with or without weight related complications at screening.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

For participants with T2D at screening:

- Diagnosed with T2D greater than or equal to 180 days prior to the day of screening

Treated with either:

  • Diet and exercise alone or with 1-3 marketed oral antidiabetic drugs (metformin, alpha glucosidase, Sulfonylureas (SU), glinides, sodium-glucose co-transporter 2 inhibitors (SGLT2i) or glitazone as a single agent or in combination) according to local label.
  • Treatment with oral anti-diabetic drugs should be stable (same drug(s) or active ingredient, dose, and dosing frequency) for at least 60 days before screening
  • (HbA1c) of less than or equal to 10.0 percent (less than or equal to 86 millimoles per mol [mmol/mol]) as measured by the central laboratory at screening.

Exclusion criteria

Exclusion Criteria:

  • A self-reported change in body weight greater than 5 kilograms (kg) within 90 days before screening irrespective of medical records.
  • Treatment with any medication for the indication of obesity within the past 90 days before screening.
  • Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.

For participants without T2D at screening:

- greater than or equal to 6.5percent (48 mmol/mol) as measured by the laboratory.

For participants with T2D at screening:

  • Renal impairment with estimated (eGFR) value of less than 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease Improving Global Outcomes (KDIGO) 2012 classification by the central laboratory at screening.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Semaglutide 2.4 milligram (mg)

    Participants will receive once-weekly subcutaneous (s.c) injection of semaglutide for 44 weeks.

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Participants will receive once-weekly subcutaneous (s.c) injection of placebo for 44 weeks.

    Drug: Placebo

Interventions

  • Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.

  • DrugPlacebo

    Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.

07

What researchers measure

Primary outcomes

  1. Change in Body Weight (%)

    Percentage change in body weight from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  2. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)

    Number of participants who achieved ≥5% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction.

    Time frame: At end of treatment (week 44)

Secondary outcomes

  1. Number of Participants Who Achieved Body Weight Reduction ≥ 10% (Yes/No)

    Number of participants who achieved ≥10% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction.

    Time frame: At end of treatment (week 44)

  2. Change in Waist Circumference

    Change in waist circumference from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  3. Change in Body Weight (kg)

    Change in body weight in kilogram (kg) from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  4. Change in Body Mass Index

    Change in body mass index from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  5. Change in Waist-height Ratio (WtHR)

    Change in waist-height ratio (WtHR) from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  6. Change in Systolic Blood Pressure

    Change in systolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  7. Change in Diastolic Blood Pressure

    Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented

    Time frame: Baseline (week 0), end of treatment (week 44)

  8. Change in Total Cholesterol (mmol/L) - Ratio to Baseline

    Change in total cholesterol measured in millimoles per liter (mmol/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

    Time frame: Baseline (week 0), end of treatment (week 44)

  9. Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in high density lipoprotein (HDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

    Time frame: Baseline (week 0), end of treatment (week 44)

  10. Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in low density lipoprotein (LDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

    Time frame: Baseline (week 0), end of treatment (week 44)

  11. Change in Very Low-Density Lipoproteins (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in VLDL cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

    Time frame: Baseline (week 0), end of treatment (week 44)

  12. Change in Triglycerides (mmol/L) - Ratio to Baseline

    Change in triglycerides measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

    Time frame: Baseline (week 0), end of treatment (week 44)

  13. Change in Free Fatty Acids (mmol/L) - Ratio to Baseline

    Change in free fatty acids measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

    Time frame: Baseline (week 0), end of treatment (week 44)

  14. Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline

    Change in high sensitivity C-Reactive Protein (hsCRP) measured in milligram per litre (mg/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

    Time frame: Baseline (week 0), end of treatment (week 44)

  15. Change in HbA1c (%)

    Change in glycosylated haemoglobin (HbA1c) in percentage from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  16. Change in HbA1c (mmol/Mol)

    Change in HbA1c measured in millimoles per mole (mmol/mol) from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  17. Change in Fasting Plasma Glucose (mg/dL)

    Change in fasting plasma glucose (FPG) measured in milligrams per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  18. Change in Fasting Plasma Glucose (mmol/L)

    Change in FPG measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  19. Number of Treatment Emergent Adverse Events (TEAEs)

    Number of TEAEs from baseline (week 0) to end of study (week 49) is presented. An adverse event is any untoward medical occurrence in a clinical trial participant that is temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP.

    Time frame: From baseline (week 0) to end of study (week 49)

  20. Number of Serious Adverse Events (SAEs)

    Number of SAEs from baseline (week 0) to end of study (week 49) is presented. A serious adverse event (SAE) is any untoward medical occurrence that fulfils at least one of following criteria: results in death; is life-threatening; requires inpatient or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect; important medical event.

    Time frame: From baseline (week 0) to end of study (week 49)

  21. Change in Pulse

    Change in pulse from baseline (week 0) to end of treatment (week 44) is presented.

    Time frame: Baseline (week 0), end of treatment (week 44)

  22. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) Less Than (<) 3.0 mmol/L Confirmed by Blood Glucose (BG) Meter - Participants With Type 2 Diabetes (T2D)

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L) confirmed by BG meter for participants with T2D from baseline (week 0) to end of study (week 49) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than 3.0 mmol/L (54 mg/dL) confirmed by BG meter.

    Time frame: From baseline (week 0) to end of study (week 49)

08

Results

Posted May 18, 2026

Participant flow

The trial was conducted at 19 sites across mainland China and Taiwan.

Participant flow — Overall Study
MilestoneSemaglutide 2.4 mgPlacebo
Started16181
Full analysis set16181
Safety analysis set16181
Completed16179
Not completed02
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryChange in Body Weight (%)

Percentage change in body weight from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Percentage change in body weight
Change in Body Weight (%)
Percentage change in body weightSemaglutide 2.4 mgPlacebo
Change in Body Weight (%)-12.2 ± 8.2-2.2 ± 5.4
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · ANCOVA · p = <0.0001 · Treatment difference: -9.87 · 95% CI -11.78 to -7.96
PrimaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)

Number of participants who achieved ≥5% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction.

Time frame:
At end of treatment (week 44)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes12819
No3159
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 14.83 · 95% CI 7.42 to 29.63
SecondaryNumber of Participants Who Achieved Body Weight Reduction ≥ 10% (Yes/No)

Number of participants who achieved ≥10% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction.

Time frame:
At end of treatment (week 44)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction ≥ 10% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes969
No6369
SecondaryChange in Waist Circumference

Change in waist circumference from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Centimeter (cm)
Change in Waist Circumference
Centimeter (cm)Semaglutide 2.4 mgPlacebo
Change in Waist Circumference-9.1 ± 6.2-2.4 ± 5.0
SecondaryChange in Body Weight (kg)

Change in body weight in kilogram (kg) from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Kg
Change in Body Weight (kg)
KgSemaglutide 2.4 mgPlacebo
Change in Body Weight (kg)-9.3 ± 6.1-1.7 ± 4.3
SecondaryChange in Body Mass Index

Change in body mass index from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Kilogram per square meter (kg/m^2)
Change in Body Mass Index
Kilogram per square meter (kg/m^2)Semaglutide 2.4 mgPlacebo
Change in Body Mass Index-3.4 ± 2.3-0.6 ± 1.5
SecondaryChange in Waist-height Ratio (WtHR)

Change in waist-height ratio (WtHR) from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Ratio of waist-height
Change in Waist-height Ratio (WtHR)
Ratio of waist-heightSemaglutide 2.4 mgPlacebo
Change in Waist-height Ratio (WtHR)-0.05 ± 0.04-0.01 ± 0.03
SecondaryChange in Systolic Blood Pressure

Change in systolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Millimeter of mercury (mmHg)
Change in Systolic Blood Pressure
Millimeter of mercury (mmHg)Semaglutide 2.4 mgPlacebo
Change in Systolic Blood Pressure-7 ± 13-4 ± 10
SecondaryChange in Diastolic Blood Pressure

Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure
mmHgSemaglutide 2.4 mgPlacebo
Change in Diastolic Blood Pressure-4 ± 9-2 ± 8
SecondaryChange in Total Cholesterol (mmol/L) - Ratio to Baseline

Change in total cholesterol measured in millimoles per liter (mmol/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Total Cholesterol (mmol/L) - Ratio to Baseline
Ratio of total cholesterolSemaglutide 2.4 mgPlacebo
Change in Total Cholesterol (mmol/L) - Ratio to Baseline0.94 ± 16.51.01 ± 13.1
SecondaryChange in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in high density lipoprotein (HDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of HDL
Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of HDLSemaglutide 2.4 mgPlacebo
Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline1.04 ± 13.81.06 ± 13.7
SecondaryChange in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in low density lipoprotein (LDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of LDL
Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of LDLSemaglutide 2.4 mgPlacebo
Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline0.97 ± 24.41.02 ± 24.1
SecondaryChange in Very Low-Density Lipoproteins (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in VLDL cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of VLDL
Change in Very Low-Density Lipoproteins (VLDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of VLDLSemaglutide 2.4 mgPlacebo
Change in Very Low-Density Lipoproteins (VLDL) Cholesterol (mmol/L) - Ratio to Baseline0.72 ± 44.20.93 ± 38.8
SecondaryChange in Triglycerides (mmol/L) - Ratio to Baseline

Change in triglycerides measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of triglycerides
Change in Triglycerides (mmol/L) - Ratio to Baseline
Ratio of triglyceridesSemaglutide 2.4 mgPlacebo
Change in Triglycerides (mmol/L) - Ratio to Baseline0.71 ± 46.50.91 ± 44.5
SecondaryChange in Free Fatty Acids (mmol/L) - Ratio to Baseline

Change in free fatty acids measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of free fatty acids
Change in Free Fatty Acids (mmol/L) - Ratio to Baseline
Ratio of free fatty acidsSemaglutide 2.4 mgPlacebo
Change in Free Fatty Acids (mmol/L) - Ratio to Baseline0.88 ± 60.20.99 ± 61.5
SecondaryChange in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline

Change in high sensitivity C-Reactive Protein (hsCRP) measured in milligram per litre (mg/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of hsCRP
Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline
Ratio of hsCRPSemaglutide 2.4 mgPlacebo
Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline0.69 ± 154.30.68 ± 118.2
SecondaryChange in HbA1c (%)

Change in glycosylated haemoglobin (HbA1c) in percentage from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Percentage of HbA1c
Change in HbA1c (%)
Percentage of HbA1cSemaglutide 2.4 mgPlacebo
Change in HbA1c (%)-0.4 ± 0.50.0 ± 0.3
SecondaryChange in HbA1c (mmol/Mol)

Change in HbA1c measured in millimoles per mole (mmol/mol) from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · mmol/mol
Change in HbA1c (mmol/Mol)
mmol/molSemaglutide 2.4 mgPlacebo
Change in HbA1c (mmol/Mol)-4.2 ± 5.90.5 ± 3.6
SecondaryChange in Fasting Plasma Glucose (mg/dL)

Change in fasting plasma glucose (FPG) measured in milligrams per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · mg/dL
Change in Fasting Plasma Glucose (mg/dL)
mg/dLSemaglutide 2.4 mgPlacebo
Change in Fasting Plasma Glucose (mg/dL)-12.3 ± 18.40.5 ± 14.5
SecondaryChange in Fasting Plasma Glucose (mmol/L)

Change in FPG measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (mmol/L)
mmol/LSemaglutide 2.4 mgPlacebo
Change in Fasting Plasma Glucose (mmol/L)-0.7 ± 1.00.0 ± 0.8
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

Number of TEAEs from baseline (week 0) to end of study (week 49) is presented. An adverse event is any untoward medical occurrence in a clinical trial participant that is temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP.

Time frame:
From baseline (week 0) to end of study (week 49)
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsSemaglutide 2.4 mgPlacebo
Number of Treatment Emergent Adverse Events (TEAEs)614183
SecondaryNumber of Serious Adverse Events (SAEs)

Number of SAEs from baseline (week 0) to end of study (week 49) is presented. A serious adverse event (SAE) is any untoward medical occurrence that fulfils at least one of following criteria: results in death; is life-threatening; requires inpatient or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect; important medical event.

Time frame:
From baseline (week 0) to end of study (week 49)
Reported as:
Number · Events
Number of Serious Adverse Events (SAEs)
EventsSemaglutide 2.4 mgPlacebo
Number of Serious Adverse Events (SAEs)143
SecondaryChange in Pulse

Change in pulse from baseline (week 0) to end of treatment (week 44) is presented.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Beats per minute (Beats/min)
Change in Pulse
Beats per minute (Beats/min)Semaglutide 2.4 mgPlacebo
Change in Pulse3 ± 111 ± 9
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) Less Than (<) 3.0 mmol/L Confirmed by Blood Glucose (BG) Meter - Participants With Type 2 Diabetes (T2D)

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L) confirmed by BG meter for participants with T2D from baseline (week 0) to end of study (week 49) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than 3.0 mmol/L (54 mg/dL) confirmed by BG meter.

Time frame:
From baseline (week 0) to end of study (week 49)
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) Less Than (<) 3.0 mmol/L Confirmed by Blood Glucose (BG) Meter - Participants With Type 2 Diabetes (T2D)
EpisodesSemaglutide 2.4 mgPlacebo
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) Less Than (<) 3.0 mmol/L Confirmed by Blood Glucose (BG) Meter - Participants With Type 2 Diabetes (T2D)10

Adverse events

Collected over From baseline (week 0) to end of study (week 49). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sema 2.4 mg0/161 (0%)13/161 (8.1%)113/161 (70.2%)
Placebo0/81 (0%)3/81 (3.7%)26/81 (32.1%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventSema 2.4 mgPlacebo
Angina unstableCardiac disorders0/1611/81
Patellofemoral pain syndromeMusculoskeletal and connective tissue disorders0/1611/81
Pyelonephritis acuteInfections and infestations0/1611/81
Abdominal painGastrointestinal disorders1/1610/81
CholecystitisHepatobiliary disorders1/1610/81
CholelithiasisHepatobiliary disorders1/1610/81
Clavicle fractureInjury, poisoning and procedural complications1/1610/81
Dermatitis atopicSkin and subcutaneous tissue disorders1/1610/81
Endometrial hyperplasiaReproductive system and breast disorders1/1610/81
HydronephrosisRenal and urinary disorders1/1610/81
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSema 2.4 mgPlacebo
Decreased appetiteMetabolism and nutrition disorders31/1612/81
DiarrhoeaGastrointestinal disorders30/1616/81
NauseaGastrointestinal disorders29/1612/81
Upper respiratory tract infectionInfections and infestations28/16112/81
ConstipationGastrointestinal disorders22/1613/81
NasopharyngitisInfections and infestations16/1612/81
VomitingGastrointestinal disorders16/1610/81
Abdominal distensionGastrointestinal disorders13/1611/81
DizzinessNervous system disorders13/1612/81
DyspepsiaGastrointestinal disorders13/1610/81

Baseline characteristics

Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(Years)Semaglutide 2.4 mgPlaceboTotal
Mean42 ± 1041 ± 1241 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 2.4 mgPlaceboTotal
Female7942121
Male8239121
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 2.4 mgPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino16181242
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Semaglutide 2.4 mgPlaceboTotal
American Indian or Alaska Native000
Asian16181242
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
09

Study locations

21 sites
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • Chongqing University Three Gorges Hospital
    Chongqing, Chongqing Municipality 404000, China
  • Fujian Medical University Union Hospital-Endocrinology
    Fuzhou, Fujian 350001, China
  • Huizhou Central People's Hospital-Endocrinology
    Huizhou, Guangdong 516001, China
  • Hengshui People's Hospital (Harrison International Peace Hospital)-Endocrinology
    Hengshui, Hebei 053000, China
  • Shiyan Taihe Hospital (Affiliated Hospital of Hubei University of Medicine)-Endocrinology
    Shiyan, Hubei 442008, China
  • Changzhou No.2 People's Hospital, Yanghu Branch
    Changzhou, Jiangsu 213003, China
  • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
    Nanjing, Jiangsu 210011, China
  • The Second Affiliated Hospital of Nanjing Medical University_Nanjing
    Nanjing, Jiangsu 210011, China
  • The Affiliated Hospital of Jiangsu University-Endocrinology
    Zhenjiang, Jiangsu 212001, China
  • The First Bethune hospital of Jilin University-Endocrinology
    Changchun, Jilin 130061, China
  • Qinghai Provincial People's Hospital
    Xining, Qinghai 810007, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Shanghai Fifth People's Hospital-Endocrinology
    Shanghai, Shanghai Municipality 200240, China
  • Tongren Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200336, China
  • Shanghai Pudong New Area People's Hospital-Endocrinology
    Shanghai, Shanghai Municipality 201200, China
  • Ditmanson Medical Foundation Chia-Yi Christian Hospital
    Chiayi City, 600, Taiwan
  • China Medical University Hospital
    Taichung, 404, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital_main
    Taipei, 100, Taiwan
  • Taipei Medical University Hospital
    Taipei, 110, Taiwan
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Data sharing details ↗ · novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Apr 2025, 18 months.

Results were first posted in May 2026, 1 year 1 month after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 18 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 18, 2023
StartActual
Sep 15, 2023
Primary completionActual
Apr 2, 2025
CompletionActual
May 7, 2025
Results first posted
May 18, 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT06041217
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Sep 15, 2023
Primary completion
Apr 2, 2025
Completion
May 7, 2025
Results posted
May 18, 2026
Last update
May 18, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion